Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms

Science Translational Medicine

Volumn 10, Issue 436, 2018, Pages

  Wolach, Ofir ^a,b,c   Sellar, Rob S ^a,d,e   Martinod, Kimberly ^f   Cherpokova, Deya ^f   McConkey, Marie ^a   Chappell, Ryan J ^a   Silver, Alexander J ^a   Adams, Dylan ^a   Castellano, Cecilia A ^a   Schneider, Rebekka K ^a,g   Padera, Robert F ^f   DeAngelo, Daniel J ^h   Wadleigh, Martha ^h   Steensma, David P ^h   Galinsky, Ilene ^h   Stone, Richard M ^h   Genovese, Giulio ^e,i   McCarroll, Steven A ^e,i   Iliadou, Bozenna ^j   Hultman, Christina ^j   Neuberg, Donna ^h   Mullally, Ann ^a,e,h   Wagner, Denisa D ^f   Ebert, Benjamin L ^a,e,h   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DORNASE ALFA; DOUBLE STRANDED DNA; HISTONE H3; JANUS KINASE 2; JANUS KINASE INHIBITOR; MESSENGER RNA; PEPTIDYL ARGININE DEIMINASE 4; PROTEIN ARGININE DEIMINASE; RUXOLITINIB; UNCLASSIFIED DRUG; HYDROLASE; JAK2 PROTEIN, MOUSE; JANUS KINASE; PEPTIDYLARGININE DEIMINASE 4, MOUSE; PYRAZOLE DERIVATIVE; STAT PROTEIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CITRULLINATION; CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; EXTRACELLULAR TRAP; HEMATOPOIESIS; HUMAN; HUMAN CELL; INFERIOR CAVA VEIN OBSTRUCTION; JAK-STAT SIGNALING; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MOUSE; MOUSE MODEL; MYELOPROLIFERATIVE NEOPLASM; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA; THROMBOCYTE AGGREGATION; THROMBOSIS; VEIN THROMBOSIS; ANIMAL; CASE CONTROL STUDY; CELL PROLIFERATION; FEMALE; HEMATOLOGIC DISEASE; METABOLISM; MYELOPROLIFERATIVE DISORDER; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CASE-CONTROL STUDIES; CELL PROLIFERATION; EXTRACELLULAR TRAPS; FEMALE; HEMATOLOGIC NEOPLASMS; HYDROLASES; JANUS KINASE 2; JANUS KINASES; MICE; MYELOPROLIFERATIVE DISORDERS; PYRAZOLES; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; THROMBOSIS;

EID: 85045344649     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aan8292     Document Type: Article

References (40)

1. T. Klampfl, H. Gisslinger, A. S. Harutyunyan, H. Nivarthi, E. Rumi, J. D. Milosevic, N. C. C. Them, T. Berg, B. Gisslinger, D. Pietra, D. Chen, G. I. Vladimer, K. Bagienski, C. Milanesi, I. C. Casetti, E. Sant'Antonio, V. Ferretti, C. Elena, F. Schischlik, C. Cleary, M. Six, M. Schalling, A. Schönegger, C. Bock, L. Malcovati, C. Pascutto, G. Superti-Furga, M. Cazzola, R. Kralovics, Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med. 369, 2379-2390 (2013).
2. T. Barbui, G. Finazzi, A. Falanga, Myeloproliferative neoplasms and thrombosis. Blood 122, 2176-2184 (2013).
3. A. M. Vannucchi, P. Guglielmelli, JAK2 mutation-related disease and thrombosis. Semin. Thromb. Hemost. 39, 496-506 (2013).
4. T. Barbui, A. Masciulli, M. R. Marfisi, G. Tognoni, G. Finazzi, A. Rambaldi, A. Vannucchi, White blood cell counts and thrombosis in polycythemia vera: A subanalysis of the CYTO-PV study. Blood 126, 560-561 (2015).
5. R. Landolfi, L. Di Gennaro, T. Barbui, V. De Stefano, G. Finazzi, R. Marfisi, G. Tognoni, R. Marchioli; European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP), Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109, 2446-2452 (2007).
6. P. J. Campbell, C. MacLean, P. A. Beer, G. Buck, K. Wheatley, J.-J. Kiladjian, C. Forsyth, C. N. Harrison, A. R. Green, Correlation of blood counts with vascular complications in essential thrombocythemia: Analysis of the prospective PT1 cohort. Blood 120, 1409-1411 (2012).
7. A. Carobbio, E. Antonioli, P. Guglielmelli, A. M. Vannucchi, F. Delaini, V. Guerini, G. Finazzi, A. Rambaldi, T. Barbui, Leukocytosis and risk stratification assessment in essential thrombocythemia. J. Clin. Oncol. 26, 2732-2736 (2008).
8. T. Barbui, A. Carobbio, F. Cervantes, A. M. Vannucchi, P. Guglielmelli, E. Antonioli, A. Alvarez-Larrán, A. Rambaldi, G. Finazzi, G. Barosi, Thrombosis in primary myelofibrosis: Incidence and risk factors. Blood 115, 778-782 (2010).
9. V. Buxhofer-Ausch, H. Gisslinger, J. Thiele, B. Gisslinger, H.-M. Kvasnicka, L. Müllauer, S. Frantal, A. Carobbio, F. Passamonti, E. Rumi, M. Ruggeri, F. Rodeghiero, M. L. Randi, I. Bertozzi, A. M. Vannucchi, E. Antonioli, G. Finazzi, N. Gangat, A. Tefferi, T. Barbui, Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. Am. J. Hematol. 87, 669-672 (2012).
10. M. Hurtado-Nedelec, M. J. Csillag-Grange, T. Boussetta, S. A. Belambri, M. Fay, B. Cassinat, M.-A. Gougerot-Pocidalo, P. M.-C. Dang, J. El-Benna, Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation. Haematologica 98, 1517-1524 (2013).
11. A. Falanga, M. Marchetti, Thrombosis in myeloproliferative neoplasms. Semin. Thromb. Hemost. 40, 348-358 (2014).
12. M. Kushnir, H. W. Cohen, H. H. Billett, Persistent neutrophilia is a marker for an increased risk of venous thrombosis. J. Thromb. Thrombolysis 42, 545-551 (2016).
13. B. D. Vadher, S. J. Machin, K. G. Patterson, C. Sukhu, H. Walker, Life-threatening thrombotic and haemorrhagic problems associated with silent myeloproliferative disorders. Br. J. Haematol. 85, 213-216 (1993).
14. V. Brinkmann, U. Reichard, C. Goosmann, B. Fauler, Y. Uhlemann, D. S. Weiss, Y. Weinrauch, A. Zychlinsky, Neutrophil extracellular traps kill bacteria. Science 303, 1532-1535 (2004).
15. K. Martinod, D. D. Wagner, Thrombosis: Tangled up in NETs. Blood 123, 2768-2776 (2014).
16. A. L. Barnado, L. J. Crofford, J. C. Oates, At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases. J. Leukoc. Biol. 99, 265-278 (2016).
17. Y. Wang, M. Li, S. Stadler, S. Correll, P. Li, D. Wang, R. Hayama, L. Leonelli, H. Han, S. A. Grigoryev, C. D. Allis, S. A. Coonrod, Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J. Cell Biol. 184, 205-213 (2009).
18. A. Mullally, S. W. Lane, B. Ball, C. Megerdichian, R. Okabe, F. Al-Shahrour, M. Paktinat, J. E. Haydu, E. Housman, A. M. Lord, G. Wernig, M. G. Kharas, T. Mercher, J. L. Kutok, D. G. Gilliland, B. L. Ebert, Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17, 584-596 (2010).
19. K. Martinod, M. Demers, T. A. Fuchs, S. L. Wong, A. Brill, M. Gallant, J. Hu, Y. Wang, D. D. Wagner, Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc. Natl. Acad. Sci. U.S.A. 110, 8674-8679 (2013).
20. A. Brill, T. A. Fuchs, A. S. Savchenko, G. M. Thomas, K. Martinod, S. F. De Meyer, A. A. Bhandari, D. D. Wagner, Neutrophil extracellular traps promote deep vein thrombosis in mice. J. Thromb. Haemost. 10, 136-144 (2012).
21. T. A. Fuchs, A. Brill, D. Duerschmied, D. Schatzberg, M. Monestier, D. D. Myers Jr., S. K. Wrobleski, T. W. Wakefield, J. H. Hartwig, D. D. Wagner, Extracellular DNA traps promote thrombosis. Proc. Natl. Acad. Sci. U.S.A. 107, 15880-15885 (2010).
22. H. Meng, S. Yalavarthi, Y. Kanthi, L. F. Mazza, M. A. Elfline, C. E. Luke, D. J. Pinsky, P. K. Henke, J. S. Knight, In vivo role of neutrophil extracellular traps in antiphospholipid antibody-mediated venous thrombosis. Arthritis Rheumatol. 69, 655-667 (2017).
23. O. M. El-Sayed, N. A. Dewyer, C. E. Luke, M. Elfline, A. Laser, C. Hogaboam, S. L. Kunkel, P. K. Henke, Intact Toll-like receptor 9 signaling in neutrophils modulates normal thrombogenesis in mice. J. Vasc. Surg. 64, 1450-1458.e1 (2016).
24. V617F-driven mouse model of myeloproliferative neoplasm. Blood 124, 1136-1145 (2014).
25. H. D. Lewis, J. Liddle, J. E. Coote, S. J. Atkinson, M. D. Barker, B. D. Bax, K. L. Bicker, R. P. Bingham, M. Campbell, Y. H. Chen, C.-w. Chung, P. D. Craggs, R. P. Davis, D. Eberhard, G. Joberty, K. E. Lind, K. Locke, C. Maller, K. Martinod, C. Patten, O. Polyakova, C. E. Rise, M. Rüdiger, R. J. Sheppard, D. J. Slade, P. Thomas, J. Thorpe, G. Yao, G. Drewes, D. D. Wagner, P. R. Thompson, R. K. Prinjha, D. M. Wilson, Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat. Chem. Biol. 11, 189-191 (2015).
26. P. Li, M. Li, M. R. Lindberg, M. J. Kennett, N. Xiong, Y. Wang, PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J. Exp. Med. 207, 1853-1862 (2010).
27. V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107, 4274-4281 (2006).
28. M. Leshner, S. Wang, C. Lewis, H. Zheng, X. A. Chen, L. Santy, Y. Wang, PAD4 mediated histone hypercitrullination induces heterochromatin decondensation and chromatin unfolding to form neutrophil extracellular trap-like structures. Front. Immunol. 3, 307 (2012).
29. S. L. Wong, M. Demers, K. Martinod, M. Gallant, Y. Wang, A. B. Goldfine, C. R. Kahn, D. D. Wagner, Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. Nat. Med. 21, 815-819 (2015).
30. R. Rampal, F. Al-Shahrour, O. Abdel-Wahab, J. P. Patel, J.-P. Brunel, C. H. Mermel, A. J. Bass, J. Pretz, J. Ahn, T. Hricik, O. Kilpivaara, M. Wadleigh, L. Busque, D. G. Gilliland, T. R. Golub, B. L. Ebert, R. L. Levine, Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 123, e123-e133 (2014).
31. G. Genovese, A. K. Kähler, R. E. Handsaker, J. Lindberg, S. A. Rose, S. F. Bakhoum, K. Chambert, E. Mick, B. M. Neale, M. Fromer, S. M. Purcell, O. Svantesson, M. Landén, M. Höglund, S. Lehmann, S. B. Gabriel, J. L. Moran, E. S. Lander, P. F. Sullivan, P. Sklar, H. Grönberg, C. M. Hultman, S. A. McCarroll, Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477-2487 (2014).
32. S. Jaiswal, P. Fontanillas, J. Flannick, A. Manning, P. V. Grauman, B. G. Mar, R. C. Lindsley, C. H. Mermel, N. Burtt, A. Chavez, J. M. Higgins, V. Moltchanov, F. C. Kuo, M. J. Kluk, B. Henderson, L. Kinnunen, H. A. Koistinen, C. Ladenvall, G. Getz, A. Correa, B. F. Banahan, S. Gabriel, S. Kathiresan, H. M. Stringham, M. I. McCarthy, M. Boehnke, J. Tuomilehto, C. Haiman, L. Groop, G. Atzmon, J. G. Wilson, D. Neuberg, D. Altshuler, B. L. Ebert, Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488-2498 (2014).
33. C. P. Marin Oyarzún, A. Carestia, P. R. Lev, A. C. Glembotsky, M. A. Castro Ríos, B. Moiraghi, F. C. Molinas, R. F. Marta, M. Schattner, P. G. Heller, Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms. Sci. Rep. 6, 38738 (2016).
34. A. M. Vannucchi, J. J. Kiladjian, M. Griesshammer, T. Masszi, S. Durrant, F. Passamonti, C. N. Harrison, F. Pane, P. Zachee, R. Mesa, S. He, M. M. Jones, W. Garrett, J. Li, U. Pirron, D. Habr, S. Verstovsek, Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N. Engl. J. Med. 372, 426-435 (2015).
35. S. Verstovsek, R. A. Mesa, J. Gotlib, R. S. Levy, V. Gupta, J. F. Di Persio, J. V. Catalano, M. Deininger, C. Miller, R. T. Silver, M. Talpaz, E. F. Winton, J. H. Harvey Jr., M. O. Arcasoy, E. Hexner, R. M. Lyons, R. Paquette, A. Raza, K. Vaddi, S. Erickson-Viitanen, I. L. Koumenis, W. Sun, V. Sandor, H. M. Kantarjian, A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366, 799-807 (2012).
36. K. Martinod, T. Witsch, K. Farley, M. Gallant, E. Remold-O'Donnell, D. D. Wagner, Neutrophil elastase-deficient mice form neutrophil extracellular traps in an experimental model of deep vein thrombosis. J. Thromb. Haemost. 14, 551-558 (2016).
37. M. Demers, D. S. Krause, D. Schatzberg, K. Martinod, J. R. Voorhees, T. A. Fuchs, D. T. Scadden, D. D. Wagner, Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc. Natl. Acad. Sci. U.S.A. 109, 13076-13081 (2012).
38. D. Simon, H. U. Simon, S. Yousefi, Extracellular DNA traps in allergic, infectious, and autoimmune diseases. Allergy 68, 409-416 (2013).
39. A. S. Gonzalez, B. W. Bardoel, C. J. Harbort, A. Zychlinsky, Induction and quantification of neutrophil extracellular traps. Methods Mol. Biol. 1124, 307-318 (2014).
40. A. Quintás-Cardama, K. Vaddi, P. Liu, T. Manshouri, J. Li, P. A. Scherle, E. Caulder, X. Wen, Y. Li, P. Waeltz, M. Rupar, T. Burn, Y. Lo, J. Kelley, M. Covington, S. Shepard, J. D. Rodgers, P. Haley, H. Kantarjian, J. S. Fridman, S. Verstovsek, Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: Therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115, 3109-3117 (2010).